Answered You can buy a ready-made answer or pick a professional tutor to order an original one.
Case Study Value: (30%) Group or individual: individual Word limit: 1,500 words (+/- 10%) excluding title page and references in reference list. Words included: Introduction, Main Body, Conclusion/Rec
Case Study Value: (30%) Group or individual: individual Word limit: 1,500 words (+/- 10%) excluding title page and references in reference list. Words included: Introduction, Main Body, Conclusion/Recommendations; in-text referencing, tables). Learning Outcomes: Identify key translation science definitions and terminology Use appropriate methods to assess the quality of available evidence related to the best-practice in your field Identify knowledge translation needs in your field Identify and use key models and frameworks underpinning evidence translation Understand what constitutes a 'complex intervention' and the barriers and facilitators that may apply to implementing a complex intervention Identify key knowledge translation strategies and their evidence base Understand knowledge translation goals and how to evaluate outcomes Describe practical change facilitation strategies and sustainability approaches to knowledge translation. This assignment covers Modules 1-5 of the course content.Instructions: In your case study: I.Choose a best practice recommendation from a National or International clinical Guideline e.g. Australian Clinical Guidelines for Stroke Management (or other similar Guideline for a different condition) and critically appraise the research it is based on; II. Discuss the strength of the evidence that underpins the recommendation you have chosen: III. Evaluate / identify the service delivery compliance related to the recommendation you have chosen and reasons why an evidence-practice gap exists between the service delivery and the clinical recommendation; IV. Use one of the theoretical frameworks presented in Module 5 for analysing the determinants of implementation to structure your discussion and arguments for why some people do not receive recommended best practice. Make sure your assignment is concise and remember to proof read your work. See the Marking rubric for further detail of allocation of marks within the assignment. Add your total words (minus references) at the beginning of your assignment.
- ANSWER
-
Tutor has posted answer for $10.00. See answer's preview
********************** 1: *** Use ** *************** ** ****** and ******** COVID-19 CasesName:Course:Institution:Instructor: Date: IntroductionDuring the ******** ******** ***** Health ************ *** **** ********* *** vigilant to **** ******* manage ** *** ** *** **** *** ************ ******** ********** *** *** *** of *** *************** *** *** use ** *************** *** ******* in severe *** ******** ******** ********** **** Paassen ** ** ***** ** **** this ***** ******** ** **** **** practice **** ** through critically ********** ** examining *** ******** and depth of ******** guiding *** recommendations *** ******* *** ** ********** testing ******** trials *** ************* Moreover this ***** **** ****** *** ***** ** ********** ** ***** ** ******* ******** **** **** ************** **** ******** **** ****** ** identify **** that have been ********* full implementation ** ******** **** study **** utilise *** ********* ** ****** (KTA) framework ** explore *** determinants ** its ************** *** **** ********** ** how ** ****** the ***************** *** According to ** ****** ****** *** ** * ***** ********* ** *********** ******* as it ***** ********** *** *** ******* ******** ******** *** ********** research thus *** ********* of use ** scientific *********** *** healthcare ********************** and ******** Appraisal of *** Best PracticeIn ********* **** *** *********** the use of *************** ** circumstances ** ****** *** ******** ********** ***** ******** of ******** ** ******* **** ************** ** was ***** a ******* and multi-national ********** ******* trial *** meta-analysis ** *** *** ** corticosteroids *** ************ ******** The *** ******** ** countries **** a ***** of *** *** ******** ************* ** it ******* **** January 2020 and *** ********* 2022 **************** ** ** ***** ********* **** ***** ** ****** that *************** *** effective in ********* ****** ******** outcomes and ******** ********* ***** ** ****** *** America *** acceptance ** this drug *** **** ******** ** ****** World ****** ************ ******** * suitable ******* for **** ************** ** one *** ****** ****** ******** **** they have signs ** ********* ****** *********** distress *** their ***** ****** ***** is *** A ******* *** critical ******** **** **** **** **** sustaining treatment **** acute *********** ******** syndrome or **** septic ******** **** 2023)Strength of *** EvidenceThere ** vast ******** that *** **** researched ****** ** support the *** ** *************** *** of *** vital ******** projects ********* *** *** RCTs ****** multiple ********* ******* *** lens ** *** guidelines This research showed **** patients who *********** ** **** ***** ****** *********** *********** ** ***** clinical ***** *** ******** *** ******** ********* ** ********* **** ********* *** ******** patients ******** ************* ***** *** ************ *** use by WHO ********* Collaborative ***** ****** To affirm ***** ******** * ********** ************* was **** to ******* *** results ****** different **** and settingOne ****** ** evidence supporting use ** *************** ** ********* ** ******** ******** 7000 ******** ** * combination ** 8 ******** ****** This study *********** that ************* ******* ********* rate ** 20% ************* one ***** ***** patients ************ **** severe *** ******** conditions ********* ******** ********** *********** *** ** * ***** ***** those *** **** not ********** ******** mechanical *********** *** receiving ****** (WHO ******* *** **** of **** ******** there have **** ******* ******* conducted ** ***** the *********** ** *************** *** ** *** ********** meta-analyses *** the Rapid Evidence ********* for COVID-19 ********* **** ***** ******** ********** **** from * previous **** ******* This ************* found **** ****************** ******** **** ***** **** ** placebo *** ********** **** ***** ****** ********* ************ (Sterne et ** ***** *** use ** a ***** ****** **** of ************ across *** ******* ********* setting *** *** groups ***** *** ***** analysis ******** ** ***** ** *** ******* *** *** ** corticosteroids ** **** to 2019 * ****** was ********* ** ********** nations and ********* that dexamethasone ****** about US$033 **** ***** Figure 11 ***** ***** evidence for *** of *********************** *********** ********************** *** *** Service ******** ***************** *** presence of evidence ** support the ******** *********** ** *************** *** severe *** ******** COVID-19 there ****** *** evidence-practice *** **** cannot be overlooked ** its ************** ********* to ********** ** al ***** ******* ******* **** ********** **** *** ******* ******** ********** and *********** ** ********** ************** ****** *** ***** *** ******** ******** ******** In ******** to that ***** ** * ********* in terms ** ********** with ********** guidelines **** ******** ****** ***** ********** in ***** ** adherence ** *** ************** hence ** ********* *********** ** *** ********** ** *********************** ***** this ******* ********* ** ** (2024) ****** **** ********* ******* **** ********* abilities ***** ******** *** ************ ** healthcare ********* *** ******* in this **** *************** ***** its ************ ******** ** **** **** ********* ******* ********* ** *** ********** ** ******** logistic is ******* ********* ********** **** ****** ** ***** ***** ************ ********** ******** forcing them to ****** the *** ********** ***** on ***** abilitiesHealthcare ****************** aspect ******* accessibility to care units qualified ********* *** the ************** ***** ******** ***** ***** ****** how * ******* ******** ******** the ********** to *** ***** *** example ** ******** ****** *** ***** second *** third waves ***** were ******* ***** ***** fourth *** ***** ***** of ***** *** ******* variant ************ in this **** healthcare facilities **** *********** ***** ****** ** ********* to observe given directives ****** et ** ************* ******** ************* ********* ******* ********** ********* **** ********* ********* and *********** **** *********** **** ** ********* *********** ** *************** ********** ** ** 2024) *** ******* ** * ********** ******** its personnel ***** ******** ** use *************** ********* ******** from their ******** ***** ******* **** ******* According ** *** ****** *** of corticosteroids *** more **** * ***** *** ***** ******* ****** **** ** hypertension ************* ******* fluid ********* ****** issues and ******** ** ******* *********** ********** ******** *** be ******* the ******** ********** *********** ** *** *** patients **** ********** ********** **** ** ******** cancer *** ******* ******** **** *** ** ********** with *** ****** recommendation ** ******** ** international ****** bodies ****** ** ***** ***** some ** *** factors that ********* clinical ***************** ******** ** ** *************** ***** *** ******************* (KTA) **************************** ***** Framework is ******** ** *** key ***** the ********* creation ** action ***** which *** ********* ** *********** evidence into ******** ***** *** ****** ***** ** the case ** recommendation ** *** of *************** *** ******* analysis through *** **** ** ********* adaption ********** of ******** *** ********** ********* ******************** CreationThe ************** of *** use ** corticosteroids ** *** *** ***** ** wide and ****** ******** This ********* *** ******** from ******* ******* such ** clinical ***** ************* ********** reviews **** ** the notable ******* *** ***** conducted ****** the ****** of January ** ********* **** include *** REACT ******** trail CAPE ***** trail and ************* ********* to ****** ** al (2020) ***** ***** established that dexamethasone *** beneficial *** ******** ******** **** severe ******* ******** ******* ** ********** and ******* ***** **** ******* in ***** of ***** ********* therefore contributing ** ******* ******** In **** context ******* *** ******** of the drugs were *** **** ************* to ensure that ******** of *** ************** *** ***** ** the highest ******* ******** ******* which *** *********** generated *** ** ********* precisely **** actionable ******** *************** CycleKnowledge adaptation *** ******** evaluationIt is ******* ** **** *** WHO ********** tailored **** that **** **** a ********** country’s healthcare ****** ******* *** scope ** ***** ********* *** ******** **** To ****** ** **** ***** training ******** **** to ** ********* to ensure effective ******** ** the ************** For example the **** of ************* was ********** **** ********** by *** **** ***** ***** ************* at * ***** ****** ** ****** **** 2023) More assistance is ******** to ****** ********** more ** in *** line ** ****** ***** **** as Oxygen ********* As such ************* ***** ********** is ***** such **** ********* challenges *** ** overcomeMonitoring and ************ *** ***** of ******** *** recommendation monitoring through surveillance ****** ******* ********** ******* ** ***** ********** ** ********** can help ******** gaps in ******** ********* *** ***** ************ *** ****** ********* ******* ** ** ***** ********* ** al (2021) points **** *** ********* * comprehensive monitoring system through mechanisms such ** ****** **** ********** ***** ******** Appraisal *** ******** ********* ******* ***** and ************* with ******* ******** ****** *********** ****** ** ** ****** ***** that *** ******** ********** ********** ******* can ********* ********** ****** ******* **** ***** clinical ******** *** ******* ******** ** ********* ******** **** **** ** mechanism can **** **** ******** ****** *** **** ******** ***** ****** *********************** *** ***************** the ******* ******* ****** from ******* ******* *** *** clinical use ** *************** ***** ****** several ********** that ****** *********** of the ******** ** ******** **** ******** ******** *** ***** to ** ********* through ************ **** **** **** the *** ********** *** ** adapted seamlessly **** ********* nations ** per ***** ***** ******** ** **** ** ******** ********** the ******** ********** systems face *** ****** ****** monitoring mechanism **** **** ********** is ********** ** *** **** **** ********* ** ** 2021) *** recommendations ***** *** ** ***** in bridging *** evidence ** ******** *** Figure ** below ***** * ********* **** *** ** pursued to ****** *** *** ******* ******** and **************** (Flaherty ************** ******** ******** ******* healthcare ********* *** *** hands ** ********** *** ********* **** that **** improve ***** skills knowledge *** ********** (van Diggele et al 2020)2Improve ********** ****** ****** such **** ********* that support *** ************** are ******* and ********** ****** *** *********** are ******************* ********** ************** **** ** **** having adequate ********* and ************ ** care *** **** ******** ********** ** best practices4One ** the ways ** ******* ***************** *** ** ******* ********** ********** ** ***** ** compliance **** *** ** ******* *********** of ******** metric ** *********** ******** and ****** timely feedback ********** (Skivington ** al ****************************** * ***** * A ****** * * ***** ****** * * ****** ********** ********** ********** ** *********** ** ******** Disaster ***** *** Outcomes: ****** ****** COVID-19 ******** Recovery InHealth *********** Disasters *** ********* ****** Routledge ********* **** ************************************************************************************************************************************************************************************************************** C ***** * Aldama * Casas * Deshpande * ***** * ***** *** * ****** ** ******* ** (should) ****** ************ and ********** ****** nine ********* ****** *** ******** ******** **** *** ***** ******** Retrieved **** ************************************************ * C Kumanyika * K ******* M * ***** *********** * ****** ************** science should give ****** ******** ** ****** equity ************** ******* ** 1-16 Retrieved **** ******************************************************* * Merson * ************** B * * Burrell * * ********* * W ******** * P & Bidin * N ****** ************** of *************** ** *** *** of Corticosteroids ** ****** ************ ******* Open6(12) ***************** ********* from ***************************************** * * ***** * & Goldacre * ****** ********** **** ***** *********** ** ****** ******** ***** ******* ** ClinicalTrials **** a ****** ***** *** Lancet 395(10221) ******* ********* **** https://oraoxacuk/objects/uuid:0427c19e-a95d-4caf-978d-90f2393f8b84/files/rrj430454kDi ****** * (2023) ********* the *** *** ** ******** ********* ************* * ************* ** ****************** in ************ ******* ********* **** ******************************************* * ********** ********* * **************** * ****** * & ****** * * ****** Global challenges to ****** ****** **** ******* ****** *** ******** ********* a ****** ** ******** ******** *** *************** of ************ ************* 1295 ********* **** *********************************************** H ****** ******** *** *** ******* research *** ********* * ********** ***** *** ** integrate evidence-based ************* ** ******** practice through education Retrieved **** **************************************** * & ********** * (2020) * descriptive ********* *** the ***** ** ********* ********** ********* *** *********** Systems 62(12) 4481-4508 ********* **** **************************************************************** * ************ * * ********* Y **** B ****** * ***** * & ******* * ****** ******* *********** ********* ** ******** practice guidelines ** patients **** ********* chronic ******** syndrome: * qualitative interview ***** in the ambulatory care ****** ** ********** ****** ******** ************* *** ********* from ************************************************ ************* ***** ****** ************* ** hospitalized ******** **** *********** ******* ******* ** ************** 693-704 ********* from ********************************************************** * ******** * Simpson * * ***** * ***** J ******* J * & ***** * ****** ********* *** *** development and ********** of ******* ************** *** ******** workshop *** ********************* ****** Health ********** ********** *********** ******** ****** * ********* from *************************************** * ****** * **** * * ******* * S ****** J Angus D C & Marshall * * (2020) *********** ******* ************** ** ******** *************** *** ********* ***** ********** *** ******** with ********* a meta-analysisJama324(13) ********* Retrieved from ********************************************* ******** * Jeseňák * Solovič I ********** * Rybář * ***** ******* * ****** Adherence ** application ********* ** ******* ************** ** ******** **** ****** *** ******** ******** outcomesBMJ **** Respiratory ************* ******* ********* **** doi:101136/bmjresp-2023-001874Van ******* * Vos * * ******** * M ******* * * **** * * ***** ****** S M (2020) ************** *** ** ******** ********* a ********** review and ************* on ******** **************** ****** **** ********* **** ********************************************* ****** ************ ***** ****** Coronavirus disease (COVID-19): Corticosteroids including dexamethasone ********* from ************************************************************************************************************ (2020) Is dexamethasone * ********* *** *** ******** patients? Afghanistan Coronavirus Retrieved **** *****************************************************************************************************************************************************